Nuvalent, Inc. Class A Common Stock
NUVLNuvalent, Inc. Class A (NUVL) is a biotechnology company focused on developing targeted therapies for genetically defined cancers. It aims to create precision medicines that address unmet medical needs by leveraging molecular insights and innovative drug discovery approaches.
Company News
Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slight...
Nuvalent, a clinical-stage biotechnology company, reported a Q2 2025 net loss of $99.7 million while advancing its oncology pipeline, focusing on kinase mutation therapies for lung cancer. The company continues developing zidesamtinib and neladalkib, with potential drug launches anticipated in 2026.
Nuvalent presented positive data from its Phase 1/2 trials for zidesamtinib and NVL-655 at the ESMO Congress 2024. The company plans to initiate a Phase 3 trial for NVL-655 in the first half of 2025 and expects pivotal data from both trials in 2025. Nuvalent also announced a $350 million public offering.
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The dilution monster stalked the company following the announcement of a new capital-raising effort.
